Alexa B. Schrock
0000-0003-0106-9096
Publication & Citation Trends
Publications
0 total
Abstract PR005: KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers
Cited by 0
Semantic Scholar
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapy.
Cited by 0
Semantic Scholar
Detecting MTAP loss in liquid biopsies from patients with pancreatic ductal adenocarcinoma.
Cited by 0
Semantic Scholar
Association between ERBB2 (HER2) amplification, RNA gene expression (GE), and immunohistochemistry (IHC) in GI cancers.
Cited by 0
Semantic Scholar
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets.
Cited by 0
Semantic Scholar
Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Cited by 1
Semantic Scholar
A study of the homologous recombination deficiency signature (HRDSig) status of advanced esophageal squamous cell carcinoma (AESCC) by utilizing comprehensive genomic profiling (CGP).
Cited by 0
Semantic Scholar
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
Cited by 1
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(338)
Cancer Genomics and Diagnostics
(257)
Colorectal Cancer Treatments and Studies
(129)
HER2/EGFR in Cancer Research
(100)
Gastric Cancer Management and Outcomes
(93)
Affiliations
University of Pisa
Cedars-Sinai Medical Center
Loyola University Medical Center
Cleveland Clinic
The University of Texas MD Anderson Cancer Center